Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient-derived Organoids of RAS/RAF Wild-type Metastatic Right Colon Cancer to Test the Sensitivity and Clinical Consistency of Combined Treatment of Cetuximab.

NCT04906733 is registered in ClinicalTrials.gov with D1 Medical Technology (Shanghai) Co., Ltd, China as lead sponsor.

NCT NCT04906733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04906733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient-derived Organoids of RAS/RAF Wild-type Metastatic Right Colon Cancer to Test the Sensitivity and Clinical Consistency of Combined Treatment of Cetuximab.
Lead sponsor
D1 Medical Technology (Shanghai) Co., Ltd, China
Phase
Observational
Overall status
Unknown status
Start date
April 15, 2021
Completion date
December 31, 2023
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, metastatic cancer, organoids